RxDoctor Payments Data

Morgan Neal, OD

Optometrist · Kinston, NCNPI 1316464050

Payments from drug & device makers

$1,296in general payments, 2019–2025

Across 27 payments — averaging $48.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$802
  • Bausch & Lomb Americas Inc.$212
  • AbbVie$138
  • Oyster Point Pharma, Inc.$51
  • Coopervision Inc.$45
  • Aerie Pharmaceuticals, Inc.$37
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$1,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,296 in reported general payments places this provider in the 50th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,701
Medicare patients
349
Services billed
5,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine258$169,111
LumiganBimatoprost128$54,590
XiidraLifitegrast25$18,722
Alphagan PBrimonidine Tartrate45$8,714
Cyclosporine23$7,645
SimbrinzaBrinzolamide/Brimonidine Tart15$3,256
Latanoprost352$1,883
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat114$1,574
Brimonidine Tartrate47$1,529
Prednisolone Acetate23$697
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$351
Dorzolamide Hcl22$294
Timolol Maleate28$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$138$232,414431 claims
Bausch & Lomb Americas Inc.Xiidra$212$18,72225 claims
AlconSimbrinza$802$3,25615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Kinston

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →